Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.

ABSTRACT:

Unlabelled

Aims/Introduction:  We assessed the long-term (52 weeks) safety and efficacy of exenatide b.i.d. in Japanese patients with type 2 diabetes and suboptimal glycemic control.

Materials and methods

  Participants completing a 24-week randomized controlled trial of exenatide (5 μg, 10 μg or placebo b.i.d.) were invited to continue in a 28-week open-label extension study (5 μg, n = 64; 10 μg, n = 53). Safety measures included treatment-emergent adverse events (TEAE). Efficacy measures included change from baseline in glycosylated hemoglobin A1c (HbA1c) levels, proportion of participants achieving HbA1c target levels, fasting and seven-point, self-monitored blood glucose concentrations (SMBG), 1,5-anhydroglucitol concentrations, and bodyweight.

Results

  A total o

SUBMITTER: Inagaki N 

PROVIDER: S-EPMC4014904 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature